Cancer Stem Cell News Volume 9.27 | Jul 22 2020







2020-07-22 | CSCN 9.27


Cancer Stem Cell News by STEMCELL Technologies
Vol. 9.27 – 22 July, 2020
TOP STORY

Tumor-Initiating Cells Establish an IL-33–TGF-β Niche Signaling Loop to Promote Cancer Progression

The authors showed, using a mouse model of squamous cell carcinoma, that tumor-initiating cells played a crucial role in creating a niche microenvironment that was required for tumor progression and drug resistance.
[Science]

Abstract

Tumors Are 3D. Your 2D Model May Not Give You All The Answers. Learn More.
PUBLICATIONSRanked by the impact factor of the journal

BMI1 Inhibition Eliminates Residual Cancer Stem Cells after PD1 Blockade and Activates Antitumor Immunity to Prevent Metastasis and Relapse

Researchers showed that the combination treatment of anti-PD1 and cisplatin enriched BMI1+ CSCs in head and neck squamous cell carcinoma (HNSCC) while inhibiting HNSCC growth.
[Cell Stem Cell]

AbstractGraphical Abstract

LEFTY1 Is a Dual-SMAD Inhibitor that Promotes Mammary Progenitor Growth and Tumorigenesis

Scientists showed that LEFTY1, a secreted inhibitor of NODAL/SMAD2 signaling, was produced by mammary progenitor cells and, concomitantly, suppressed SMAD2 and SMAD5 signaling to promote long-term proliferation of normal and malignant mammary epithelial cells.
[Cell Stem Cell]

AbstractGraphical Abstract

Therapeutic Inhibition of FcγRIIb Signaling Targets Leukemic Stem Cells in Chronic Myeloid Leukemia

Investigators describe the immunoreceptor tyrosine-based inhibition motif-containing Fc gamma receptor IIb for being critical in leukemic stem cell resistance and showed that targeting FcγRIIb downstream signaling, by using a Food and Drug Administration-approved BTK inhibitor, provided a successful therapeutic approach.
[Leukemia]

Full Article

Signal-Transducing Adapter Protein-1 Is Required for Maintenance of Leukemic Stem Cells in CML

Scientists found that the expression of STAP-1 was aberrantly upregulated in chronic myeloid leukemia (CML) stem cells in patients’ bone marrow.
[Oncogene]

Abstract

Inactivating p53 Is Essential for Nerve Growth Factor Receptor to Promote Melanoma-Initiating Cell-Stemmed Tumorigenesis

Knockdown of nerve growth factor receptor (NGFR) markedly reduced the size and number of spheroid formation of melanoma cells, which could be rescued by ectopically expressed NGFR.
[Cell Death & Disease]

Full Article

Label-Free Detection of Rare Circulating Tumor Cells by Image Analysis and Machine Learning

Investigators present a method for label-free detection of circulating tumor cells from patient blood samples, by taking advantage of data analysis of bright field microscopy images.
[Scientific Reports]

Full Article

Glycosphingolipid Expression at Breast Cancer Stem Cells after Novel Thieno[2,3-B]Pyridine Anticancer Compound Treatment

Scientists performed studies of viability, type of cell death, cancer stem cell percent and glycosphingolipid expression on CSC and non-CSC after treatment of MDA-MB-231 and MDA-MB-453 triple-negative breast cancer cells with a newly developed thienopyridine anticancer compound.
[Scientific Reports]

Full Article


Watch the webinar where Dr. Suzan Imren discusses factors affecting the balance between HSC self-renewal and leukemic transformation
REVIEWS

SOX2 and p53 Expression Control Converges in PI3K/AKT Signaling with Versatile Implications for Stemness and Cancer

The authors summarize the latest advances in the understanding of PI3K/AKT/SOX2-driven stemness and its intertwined relations to p53-signaling in DNA damage response under conditions of pluripotency, reprogramming, and transformation.
[International Journal of Molecular Sciences]

Full Article

INDUSTRY AND POLICY NEWS

Karolinska Development’s Portfolio Company Aprea Therapeutics Expands Clinical Trial of Eprenetapopt for TP53 Mutant Acute Myeloid Leukemia

Karolinska Development AB announces that its portfolio company Aprea Therapeutics has decided to expand the enrollment of patients in its Phase I clinical trial evaluating eprenetapopt in TP53 mutant acute myeloid leukemia.
[Karolinska Development AB]

Press Release

Aprea Therapeutics Announces Expansion of Clinical Trial Evaluating Eprenetapopt for the Front-Line Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)

Aprea Therapeutics, Inc. announced the expansion of patient enrollment in its Phase I clinical trial evaluating eprenetapopt in TP53 mutant AML.
[Aprea Therapeutics, Inc.]

Press Release

Science Money Slashed in EU’s €1.8-Trillion Budget Deal

A historic €1.8-trillion (US$2.1-trillion) budget deal reached by European Union (EU) leaders to fund its next seven years — and its recovery from the coronavirus pandemic — has left scientists and research advocates disappointed.
[Nature News]

Editorial

FEATURED EVENT

Transcription and Chromatin

August 27 – August 29
Virtual

> See All Events

JOB OPPORTUNITIES

Postdoctoral Research Fellow – Hematopoiesis, Marrow Failure and Myeloid Leukemia

Cincinnati Children’s Hospital Medical Center – Cincinnati, Ohio, United States

Postdoctoral Positions – Cancer Epigenomics

West Virginia University – Morgantown, West Virginia, United States

Postdoctoral Researcher – RNA Epitranscriptomics and Immune Cells

Lund University – Lund, Sweden

Postdoctoral Research Fellowship – Cancer Biology

Massachusetts General Hospital – Charlestown, Massachusetts, United States

Faculty and Postdoctoral Positions – Stem Cells and Cancer

Shanghai Jiao Tong University – Shanghai, China

> See All Jobs

Submit an article, publication, job or event
Brought to you by
stemcell-logo-for newsletter-2
Cancer Stem Cell News Twitter


0
Share